BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Abiru S, Migita K, Maeda Y, Daikoku M, Ito M, Ohata K, Nagaoka S, Matsumoto T, Takii Y, Kusumoto K. Serum cytokine and soluble cytokine receptor levels in patients with non-alcoholic steatohepatitis. Liver Int. 2006;26:39-45. [PMID: 16420507 DOI: 10.1111/j.1478-3231.2005.01191.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 128] [Article Influence: 7.9] [Reference Citation Analysis]
Number Citing Articles
1 Targher G, Bertolini L, Rodella S, Zoppini G, Lippi G, Day C, Muggeo M. Non-alcoholic fatty liver disease is independently associated with an increased prevalence of chronic kidney disease and proliferative/laser-treated retinopathy in type 2 diabetic patients. Diabetologia. 2008;51:444-450. [PMID: 18058083 DOI: 10.1007/s00125-007-0897-4] [Cited by in Crossref: 198] [Cited by in F6Publishing: 174] [Article Influence: 13.2] [Reference Citation Analysis]
2 Hwang ST, Cho YK, Yun JW, Park JH, Kim HJ, Park DI, Sohn CI, Jeon WK, Kim BI, Rhee EJ. Impact of non-alcoholic fatty liver disease on microalbuminuria in patients with prediabetes and diabetes. Intern Med J. 2010;40:437-442. [PMID: 19460054 DOI: 10.1111/j.1445-5994.2009.01979.x] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 5.0] [Reference Citation Analysis]
3 Wu WY, Li J, Wu ZS, Zhang CL, Meng XL. STAT3 activation in monocytes accelerates liver cancer progression. BMC Cancer 2011;11:506. [PMID: 22136659 DOI: 10.1186/1471-2407-11-506] [Cited by in Crossref: 46] [Cited by in F6Publishing: 48] [Article Influence: 4.2] [Reference Citation Analysis]
4 Syn WK, Choi SS, Diehl AM. Apoptosis and cytokines in non-alcoholic steatohepatitis. Clin Liver Dis 2009;13:565-80. [PMID: 19818305 DOI: 10.1016/j.cld.2009.07.003] [Cited by in Crossref: 77] [Cited by in F6Publishing: 80] [Article Influence: 5.9] [Reference Citation Analysis]
5 Aparicio-Vergara M, Hommelberg PP, Schreurs M, Gruben N, Stienstra R, Shiri-Sverdlov R, Kloosterhuis NJ, de Bruin A, van de Sluis B, Koonen DP, Hofker MH. Tumor necrosis factor receptor 1 gain-of-function mutation aggravates nonalcoholic fatty liver disease but does not cause insulin resistance in a murine model. Hepatology. 2013;57:566-576. [PMID: 22941955 DOI: 10.1002/hep.26046] [Cited by in Crossref: 33] [Cited by in F6Publishing: 32] [Article Influence: 3.7] [Reference Citation Analysis]
6 Barshop NJ, Sirlin CB, Schwimmer JB, Lavine JE. Review article: epidemiology, pathogenesis and potential treatments of paediatric non-alcoholic fatty liver disease: REVIEW: PAEDIATRIC NON-ALCOHOLIC FATTY LIVER DISEASE. Alimentary Pharmacology & Therapeutics 2008;28:13-24. [DOI: 10.1111/j.1365-2036.2008.03703.x] [Cited by in Crossref: 89] [Cited by in F6Publishing: 94] [Article Influence: 6.4] [Reference Citation Analysis]
7 Lewis JR, Mohanty SR. Nonalcoholic Fatty Liver Disease: A Review and Update. Dig Dis Sci 2010;55:560-78. [DOI: 10.1007/s10620-009-1081-0] [Cited by in Crossref: 212] [Cited by in F6Publishing: 211] [Article Influence: 17.7] [Reference Citation Analysis]
8 Goyale A, Jain A, Smith C, Papatheodoridi M, Misas MG, Roccarina D, Prat LI, Mikhailidis DP, Nair D, Tsochatzis E. Assessment of non-alcoholic fatty liver disease (NAFLD) severity with novel serum-based markers: A pilot study. PLoS One 2021;16:e0260313. [PMID: 34813621 DOI: 10.1371/journal.pone.0260313] [Reference Citation Analysis]
9 Coulon S, Francque S, Colle I, Verrijken A, Blomme B, Heindryckx F, De Munter S, Prawitt J, Caron S, Staels B, Van Vlierberghe H, Van Gaal L, Geerts A. Evaluation of inflammatory and angiogenic factors in patients with non-alcoholic fatty liver disease. Cytokine 2012;59:442-9. [DOI: 10.1016/j.cyto.2012.05.001] [Cited by in Crossref: 64] [Cited by in F6Publishing: 61] [Article Influence: 6.4] [Reference Citation Analysis]
10 Perito ER, Ajmera V, Bass NM, Rosenthal P, Lavine JE, Schwimmer JB, Yates KP, Diehl AM, Molleston JP, Murray KF, Scheimann A, Gill R, Glidden D, Aouizerat B. Association Between Cytokines and Liver Histology in Children with Nonalcoholic Fatty Liver Disease. Hepatol Commun 2017;1:609-22. [PMID: 29130075 DOI: 10.1002/hep4.1068] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 3.0] [Reference Citation Analysis]
11 Carulli L, Ballestri S, Lonardo A, Lami F, Violi E, Losi L, Bonilauri L, Verrone AM, Odoardi MR, Scaglioni F. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels? Intern Emerg Med. 2013;8:297-305. [PMID: 21559749 DOI: 10.1007/s11739-011-0609-4] [Cited by in Crossref: 47] [Cited by in F6Publishing: 48] [Article Influence: 4.3] [Reference Citation Analysis]
12 Huang G, Li S, Zhang Y, Zhou X, Chen W. Vicenin-2 is a novel inhibitor of STAT3 signaling pathway in human hepatocellular carcinoma. Journal of Functional Foods 2020;69:103921. [DOI: 10.1016/j.jff.2020.103921] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
13 Li H, Toth E, Cherrington NJ. Asking the Right Questions With Animal Models: Methionine- and Choline-Deficient Model in Predicting Adverse Drug Reactions in Human NASH. Toxicol Sci 2018;161:23-33. [PMID: 29145614 DOI: 10.1093/toxsci/kfx253] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 4.0] [Reference Citation Analysis]
14 Hashem RM, Mahmoud MF, El-moselhy MA, Soliman HM. Interleukin-10 to tumor necrosis factor-alpha ratio is a predictive biomarker in nonalcoholic fatty liver disease: interleukin-10 to tumor necrosis factor-alpha ratio in steatohepatitis: . European Journal of Gastroenterology & Hepatology 2008;20:995-1001. [DOI: 10.1097/meg.0b013e3282fdf65f] [Cited by in Crossref: 13] [Cited by in F6Publishing: 3] [Article Influence: 0.9] [Reference Citation Analysis]
15 Filip R, Radzki RP, Bieńko M. Novel insights into the relationship between nonalcoholic fatty liver disease and osteoporosis. Clin Interv Aging 2018;13:1879-91. [PMID: 30323574 DOI: 10.2147/CIA.S170533] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
16 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014.00177] [Cited by in Crossref: 78] [Cited by in F6Publishing: 74] [Article Influence: 9.8] [Reference Citation Analysis]
17 Tsochatzis EA, Papatheodoridis GV, Archimandritis AJ. Adipokines in nonalcoholic steatohepatitis: from pathogenesis to implications in diagnosis and therapy. Mediators Inflamm 2009;2009:831670. [PMID: 19753129 DOI: 10.1155/2009/831670] [Cited by in Crossref: 71] [Cited by in F6Publishing: 77] [Article Influence: 5.5] [Reference Citation Analysis]
18 Stojsavljević S, Gomerčić Palčić M, Virović Jukić L, Smirčić Duvnjak L, Duvnjak M. Adipokines and proinflammatory cytokines, the key mediators in the pathogenesis of nonalcoholic fatty liver disease. World J Gastroenterol 2014; 20(48): 18070-18091 [PMID: 25561778 DOI: 10.3748/wjg.v20.i48.18070] [Cited by in CrossRef: 176] [Cited by in F6Publishing: 157] [Article Influence: 22.0] [Reference Citation Analysis]
19 Campisano S, La Colla A, Echarte SM, Chisari AN. Interplay between early-life malnutrition, epigenetic modulation of the immune function and liver diseases. Nutr Res Rev 2019;32:128-45. [PMID: 30707092 DOI: 10.1017/S0954422418000239] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
20 Carter-Kent C, Zein NN, Feldstein AE. Cytokines in the pathogenesis of fatty liver and disease progression to steatohepatitis: implications for treatment. Am J Gastroenterol. 2008;103:1036-1042. [PMID: 18177455 DOI: 10.1111/j.1572-0241.2007.01709.x] [Cited by in Crossref: 126] [Cited by in F6Publishing: 134] [Article Influence: 9.0] [Reference Citation Analysis]
21 Krawczyk M, Bonfrate L, Portincasa P. Nonalcoholic fatty liver disease. Best Pract Res Clin Gastroenterol. 2010;24:695-708. [PMID: 20955971 DOI: 10.1016/j.bpg.2010.08.005] [Cited by in Crossref: 128] [Cited by in F6Publishing: 115] [Article Influence: 11.6] [Reference Citation Analysis]
22 Machado MV, Cortez-Pinto H. Cell death and nonalcoholic steatohepatitis: where is ballooning relevant? Expert Rev Gastroenterol Hepatol. 2011;5:213-222. [PMID: 21476916 DOI: 10.1586/egh.11.16] [Cited by in Crossref: 32] [Cited by in F6Publishing: 27] [Article Influence: 2.9] [Reference Citation Analysis]
23 Hu M, Phan F, Bourron O, Ferré P, Foufelle F. Steatosis and NASH in type 2 diabetes. Biochimie 2017;143:37-41. [DOI: 10.1016/j.biochi.2017.10.019] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 6.0] [Reference Citation Analysis]
24 Owada Y, Tamura T, Tanoi T, Ozawa Y, Shimizu Y, Hisakura K, Matsuzaka T, Shimano H, Nakano N, Sakashita S. Novel non-alcoholic steatohepatitis model with histopathological and insulin-resistant features. Pathol Int. 2018;68:12-22. [PMID: 29154469 DOI: 10.1111/pin.12612] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
25 Potoupni V, Georgiadou M, Chatzigriva E, Polychronidou G, Markou E, Zapantis Gakis C, Filimidou I, Karagianni M, Anastasilakis D, Evripidou K, Ftergioti A, Togkaridou M, Tsaftaridis N, Apostolopoulos A, Polyzos SA. Circulating tumor necrosis factor-α levels in non-alcoholic fatty liver disease: A systematic review and a meta-analysis. J Gastroenterol Hepatol 2021. [PMID: 34289181 DOI: 10.1111/jgh.15631] [Reference Citation Analysis]
26 Kolodziejski PA, Leciejewska N, Chmurzynska A, Sassek M, Szczepankiewicz A, Szczepankiewicz D, Malek E, Strowski MZ, Checinska-Maciejewska Z, Nowak KW, Pruszynska-Oszmalek E. 30-Day spexin treatment of mice with diet-induced obesity (DIO) and type 2 diabetes (T2DM) increases insulin sensitivity, improves liver functions and metabolic status. Mol Cell Endocrinol 2021;536:111420. [PMID: 34384849 DOI: 10.1016/j.mce.2021.111420] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
27 Fan Y, Boivin GP, Knudsen ES, Nebert DW, Xia Y, Puga A. The aryl hydrocarbon receptor functions as a tumor suppressor of liver carcinogenesis. Cancer Res 2010;70:212-20. [PMID: 19996281 DOI: 10.1158/0008-5472.CAN-09-3090] [Cited by in Crossref: 117] [Cited by in F6Publishing: 70] [Article Influence: 9.0] [Reference Citation Analysis]
28 Simon Y, Kessler SM, Gemperlein K, Bohle RM, Müller R, Haybaeck J, Kiemer AK. Elevated free cholesterol in a p62 overexpression model of non-alcoholic steatohepatitis. World J Gastroenterol 2014; 20(47): 17839-17850 [PMID: 25548482 DOI: 10.3748/wjg.v20.i47.17839] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 21] [Article Influence: 2.1] [Reference Citation Analysis]
29 Hadizadeh F, Faghihimani E, Adibi P. Nonalcoholic fatty liver disease: Diagnostic biomarkers. World J Gastrointest Pathophysiol 2017; 8(2): 11-26 [PMID: 28573064 DOI: 10.4291/wjgp.v8.i2.11] [Cited by in CrossRef: 47] [Cited by in F6Publishing: 37] [Article Influence: 9.4] [Reference Citation Analysis]
30 Ariz U, Mato JM, Lu SC, Martínez Chantar ML. Nonalcoholic steatohepatitis, animal models, and biomarkers: what is new? Methods Mol Biol. 2010;593:109-136. [PMID: 19957147 DOI: 10.1007/978-1-60327-194-3_6] [Cited by in Crossref: 15] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
31 Alkhouri N, McCullough AJ. Noninvasive Diagnosis of NASH and Liver Fibrosis Within the Spectrum of NAFLD. Gastroenterol Hepatol (N Y). 2012;8:661-668. [PMID: 24683373 DOI: 10.1016/s0016-5085(10)62097-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
32 Dyson JK, McPherson S, Anstee QM. Republished: Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. Postgrad Med J. 2014;90:254-266. [PMID: 24737902 DOI: 10.1136/postgradmedj-2013-201620rep] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
33 Obika M, Noguchi H. Diagnosis and evaluation of nonalcoholic fatty liver disease. Exp Diabetes Res. 2012;2012:145754. [PMID: 22110476 DOI: 10.1155/2012/145754] [Cited by in Crossref: 114] [Cited by in F6Publishing: 116] [Article Influence: 10.4] [Reference Citation Analysis]
34 Braunersreuther V, Viviani GL, Mach F, Montecucco F. Role of cytokines and chemokines in non-alcoholic fatty liver disease. World J Gastroenterol 2012; 18(8): 727-735 [PMID: 22371632 DOI: 10.3748/wjg.v18.i8.727] [Cited by in CrossRef: 193] [Cited by in F6Publishing: 177] [Article Influence: 19.3] [Reference Citation Analysis]
35 Yang Z, Sun J, ji H, Shi X, Li Y, Du Z, Chen L. Pigment epithelium-derived factor improves TNFα-induced hepatic steatosis in grass carp (Ctenopharyngodon idella). Developmental & Comparative Immunology 2017;71:8-17. [DOI: 10.1016/j.dci.2017.01.016] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.4] [Reference Citation Analysis]
36 Lockman KA, Baren JP, Pemberton CJ, Baghdadi H, Burgess KE, Plevris-papaioannou N, Lee P, Howie F, Beckett G, Pryde A, Jaap AJ, Hayes PC, Filippi C, Plevris JN. Oxidative stress rather than triglyceride accumulation is a determinant of mitochondrial dysfunction in in vitro models of hepatic cellular steatosis. Liver Int 2012;32:1079-92. [DOI: 10.1111/j.1478-3231.2012.02775.x] [Cited by in Crossref: 28] [Cited by in F6Publishing: 27] [Article Influence: 2.8] [Reference Citation Analysis]
37 Gisondi P, Girolomoni G. Cardiometabolic Comorbidities and the Approach to Patients with Psoriasis. Actas Dermo-Sifiliográficas 2009;100:14-21. [DOI: 10.1016/s0001-7310(09)73373-3] [Cited by in Crossref: 21] [Cited by in F6Publishing: 4] [Article Influence: 1.6] [Reference Citation Analysis]
38 Gaddipati R, Mitnala S, Padaki N, Mukherjee RM, Sekaran A, Jayaraj-mansard M, Rabella P, Rao-guduru V, Reddy-duwuru N. Visceral adipose tissue visfatin in nonalcoholic fatty liver disease. Annals of Hepatology 2010;9:266-70. [DOI: 10.1016/s1665-2681(19)31635-7] [Cited by in Crossref: 24] [Article Influence: 2.0] [Reference Citation Analysis]
39 Naugler WE, Sakurai T, Kim S, Maeda S, Kim K, Elsharkawy AM, Karin M. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121-124. [PMID: 17615358 DOI: 10.1126/science.1140485] [Cited by in Crossref: 1224] [Cited by in F6Publishing: 1171] [Article Influence: 81.6] [Reference Citation Analysis]
40 Beltrand J, Colomb V, Marinier E, Daubrosse C, Alison M, Burcelin R, Cani PD, Chevenne D, Marchal CL. Lower insulin secretory response to glucose induced by artificial nutrition in children: prolonged and total parenteral nutrition. Pediatr Res 2007;62:624-9. [PMID: 17805200 DOI: 10.1203/PDR.0b013e3181559d5c] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
41 Youssef NA, Abdelmalek MF, Binks M, Guy CD, Omenetti A, Smith AD, Diehl AM, Suzuki A. Associations of depression, anxiety and antidepressants with histological severity of nonalcoholic fatty liver disease. Liver Int 2013;33:1062-70. [PMID: 23560860 DOI: 10.1111/liv.12165] [Cited by in Crossref: 65] [Cited by in F6Publishing: 56] [Article Influence: 7.2] [Reference Citation Analysis]
42 Alkhouri N, Feldstein AE. Noninvasive diagnosis of nonalcoholic fatty liver disease: Are we there yet? Metabolism. 2016;65:1087-1095. [PMID: 26972222 DOI: 10.1016/j.metabol.2016.01.013] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 6.7] [Reference Citation Analysis]
43 Kammoun HL, Allen TL, Henstridge DC, Kraakman MJ, Peijs L, Rose-John S, Febbraio MA. Over-expressing the soluble gp130-Fc does not ameliorate methionine and choline deficient diet-induced non alcoholic steatohepatitis in mice. PLoS One 2017;12:e0179099. [PMID: 28632778 DOI: 10.1371/journal.pone.0179099] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
44 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. IL-6 deficiency attenuates murine diet-induced non-alcoholic steatohepatitis. PLoS One. 2009;4:e7929. [PMID: 19936233 DOI: 10.1371/journal.pone.0007929] [Cited by in Crossref: 57] [Cited by in F6Publishing: 55] [Article Influence: 4.4] [Reference Citation Analysis]
45 Sangouni AA, Ghavamzadeh S, Jamalzehi A. A narrative review on effects of vitamin D on main risk factors and severity of Non-Alcoholic Fatty Liver Disease. Diabetes & Metabolic Syndrome: Clinical Research & Reviews 2019;13:2260-5. [DOI: 10.1016/j.dsx.2019.05.013] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
46 Lebensztejn DM, Kowalczuk D, Tarasów E, Skiba E, Kaczmarski M. Tumor necrosis factor alpha and its soluble receptors in obese children with NAFLD. Adv Med Sci. 2010;55:74-79. [PMID: 20371430 DOI: 10.2478/v10039-010-0008-5] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
47 Navarro-Alvarez N, Machaidze Z, Schuetz C, Zhu A, Liu WH, Shah JA, Vagefi PA, Elias N, Buhler L, Sachs DH, Markmann JF, Yeh H. Xenogeneic Heterotopic Auxiliary Liver transplantation (XHALT) promotes native liver regeneration in a Post-Hepatectomy Liver failure model. PLoS One. 2018;13:e0207272. [PMID: 30462716 DOI: 10.1371/journal.pone.0207272] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
48 Calamita G, Portincasa P. Present and future therapeutic strategies in non-alcoholic fatty liver disease. Expert Opin Ther Targets 2007;11:1231-49. [PMID: 17845148 DOI: 10.1517/14728222.11.9.1231] [Cited by in Crossref: 37] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
49 Dibra D, Xia X, Mitra A, Cutrera JJ, Lozano G, Li S. Mutant p53 in concert with an interleukin-27 receptor alpha deficiency causes spontaneous liver inflammation, fibrosis, and steatosis in mice. Hepatology 2016;63:1000-12. [PMID: 26637970 DOI: 10.1002/hep.28379] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 3.0] [Reference Citation Analysis]
50 Hosseinpour-arjmand S, Amirkhizi F, Ebrahimi-mameghani M. The effect of alpha-lipoic acid on inflammatory markers and body composition in obese patients with non-alcoholic fatty liver disease: A randomized, double-blind, placebo-controlled trial. J Clin Pharm Ther 2019;44:258-67. [DOI: 10.1111/jcpt.12784] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
51 Kobayashi T, Ogawa K, Furukawa J, Hanamatsu H, Hato M, Yoshinaga T, Morikawa K, Suda G, Sho T, Nakai M, Higashino K, Numata Y, Shinohara Y, Sakamoto N. Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. J Proteome Res 2019;18:3133-41. [DOI: 10.1021/acs.jproteome.9b00232] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
52 Mas E, Danjoux M, Garcia V, Carpentier S, Ségui B, Levade T. The pro-inflammatory action of tumour necrosis factor-α in non-alcoholic steatohepatitis is independent of the NSMAF gene product. Dig Liver Dis 2013;45:147-54. [PMID: 23044079 DOI: 10.1016/j.dld.2012.09.002] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
53 Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007;27:423-433. [PMID: 17403181 DOI: 10.1111/j.1478-3231.2007.01483.x] [Cited by in Crossref: 116] [Cited by in F6Publishing: 120] [Article Influence: 7.7] [Reference Citation Analysis]
54 den Boer M, Voshol PJ, Kuipers F, Havekes LM, Romijn JA. Hepatic steatosis: a mediator of the metabolic syndrome. Lessons from animal models. Arterioscler Thromb Vasc Biol. 2004;24:644-649. [PMID: 14715643 DOI: 10.1007/978-1-4614-0650-1_6] [Cited by in Crossref: 31] [Cited by in F6Publishing: 33] [Article Influence: 1.7] [Reference Citation Analysis]
55 Peverill W, Powell LW, Skoien R. Evolving concepts in the pathogenesis of NASH: beyond steatosis and inflammation. Int J Mol Sci 2014;15:8591-638. [PMID: 24830559 DOI: 10.3390/ijms15058591] [Cited by in Crossref: 178] [Cited by in F6Publishing: 164] [Article Influence: 22.3] [Reference Citation Analysis]
56 Pagadala M, Zein CO, Mccullough AJ. Predictors of Steatohepatitis and Advanced Fibrosis in Non-Alcoholic Fatty Liver Disease. Clinics in Liver Disease 2009;13:591-606. [DOI: 10.1016/j.cld.2009.07.011] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
57 Kim BY, Jung CH, Mok JO, Kang SK, Kim CH. Prevalences of diabetic retinopathy and nephropathy are lower in Korean type 2 diabetic patients with non-alcoholic fatty liver disease. J Diabetes Investig 2014;5:170-5. [PMID: 24843757 DOI: 10.1111/jdi.12139] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 2.3] [Reference Citation Analysis]
58 Dowman JK, Tomlinson JW, Newsome PN. Systematic review: the diagnosis and staging of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Aliment Pharmacol Ther. 2011;33:525-540. [PMID: 21198708 DOI: 10.1111/j.1365-2036.2010.04556.x] [Cited by in Crossref: 195] [Cited by in F6Publishing: 178] [Article Influence: 16.3] [Reference Citation Analysis]
59 Wang C, Yang W, Yan HX, Luo T, Zhang J, Tang L, Wu FQ, Zhang HL, Yu LX, Zheng LY, Li YQ, Dong W, He YQ, Liu Q, Zou SS, Lin Y, Hu L, Li Z, Wu MC, Wang HY. Hepatitis B virus X (HBx) induces tumorigenicity of hepatic progenitor cells in 3,5-diethoxycarbonyl-1,4-dihydrocollidine-treated HBx transgenic mice. Hepatology. 2012;55:108-120. [PMID: 21932402 DOI: 10.1002/hep.24675] [Cited by in Crossref: 96] [Cited by in F6Publishing: 99] [Article Influence: 8.7] [Reference Citation Analysis]
60 Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287:40161-40172. [PMID: 23066023 DOI: 10.10747/jbc.M112.417014] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
61 Nakaoka T, Saito Y, Saito H. Aberrant DNA Methylation as a Biomarker and a Therapeutic Target of Cholangiocarcinoma. Int J Mol Sci. 2017;18:1111. [PMID: 28545228 DOI: 10.3390/ijms18061111] [Cited by in Crossref: 17] [Cited by in F6Publishing: 21] [Article Influence: 3.4] [Reference Citation Analysis]
62 Widhalm K, Ghods E. Nonalcoholic fatty liver disease: a challenge for pediatricians. Int J Obes 2010;34:1451-67. [DOI: 10.1038/ijo.2010.185] [Cited by in Crossref: 44] [Cited by in F6Publishing: 40] [Article Influence: 3.7] [Reference Citation Analysis]
63 Targher G, Chonchol M, Bertolini L, Rodella S, Zenari L, Lippi G, Franchini M, Zoppini G, Muggeo M. Increased risk of CKD among type 2 diabetics with nonalcoholic fatty liver disease. J Am Soc Nephrol. 2008;19:1564-1570. [PMID: 18385424 DOI: 10.1681/asn.2007101155] [Cited by in Crossref: 122] [Cited by in F6Publishing: 51] [Article Influence: 8.7] [Reference Citation Analysis]
64 Green CJ, Parry SA, Gunn PJ, Ceresa CDL, Rosqvist F, Piché ME, Hodson L. Studying non-alcoholic fatty liver disease: the ins and outs of in vivo, ex vivo and in vitro human models. Horm Mol Biol Clin Investig 2018;41:/j/hmbci. [PMID: 30098284 DOI: 10.1515/hmbci-2018-0038] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.3] [Reference Citation Analysis]
65 Lickteig AJ, Fisher CD, Augustine LM, Aleksunes LM, Besselsen DG, Slitt AL, Manautou JE, Cherrington NJ. Efflux transporter expression and acetaminophen metabolite excretion are altered in rodent models of nonalcoholic fatty liver disease. Drug Metab Dispos. 2007;35:1970-1978. [PMID: 17640958 DOI: 10.1124/dmd.107.015107] [Cited by in Crossref: 68] [Cited by in F6Publishing: 69] [Article Influence: 4.5] [Reference Citation Analysis]
66 Yamada T, Obata A, Kashiwagi Y, Rokugawa T, Matsushima S, Hamada T, Watabe H, Abe K. Gd-EOB-DTPA-enhanced-MR imaging in the inflammation stage of nonalcoholic steatohepatitis (NASH) in mice. Magn Reson Imaging 2016;34:724-9. [PMID: 26979540 DOI: 10.1016/j.mri.2016.03.009] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
67 Glass O, Henao R, Patel K, Guy CD, Gruss HJ, Syn WK, Moylan CA, Streilein R, Hall R, Mae Diehl A, Abdelmalek MF. Serum Interleukin-8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease. Hepatol Commun. 2018;2:1344-1355. [PMID: 30411081 DOI: 10.1002/hep4.1237] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
68 Song D, Li C, Wang Z, Zhao Y, Shen B, Zhao W. Association of non-alcoholic fatty liver disease with diabetic retinopathy in type 2 diabetic patients: A meta-analysis of observational studies. J Diabetes Investig 2021;12:1471-9. [PMID: 33372390 DOI: 10.1111/jdi.13489] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
69 Wieckowska A, McCullough AJ, Feldstein AE. Noninvasive diagnosis and monitoring of nonalcoholic steatohepatitis: present and future. Hepatology. 2007;46:582-589. [PMID: 17661414 DOI: 10.1002/hep.21768] [Cited by in Crossref: 294] [Cited by in F6Publishing: 282] [Article Influence: 19.6] [Reference Citation Analysis]
70 Qi S, Xu D, Li Q, Xie N, Xia J, Huo Q, Li P, Chen Q, Huang S. Metabonomics screening of serum identifies pyroglutamate as a diagnostic biomarker for nonalcoholic steatohepatitis. Clin Chim Acta. 2017;473:89-95. [PMID: 28842175 DOI: 10.1016/j.cca.2017.08.022] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 3.2] [Reference Citation Analysis]
71 Gruben N, Aparicio Vergara M, Kloosterhuis NJ, van der Molen H, Stoelwinder S, Youssef S, de Bruin A, Delsing DJ, Kuivenhoven JA, van de Sluis B, Hofker MH, Koonen DP. Chemokine-like receptor 1 deficiency does not affect the development of insulin resistance and nonalcoholic fatty liver disease in mice. PLoS One 2014;9:e96345. [PMID: 24781986 DOI: 10.1371/journal.pone.0096345] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 3.4] [Reference Citation Analysis]
72 Pearce SG, Thosani NC, Pan JJ. Noninvasive biomarkers for the diagnosis of steatohepatitis and advanced fibrosis in NAFLD. Biomark Res. 2013;1:7. [PMID: 24252302 DOI: 10.1186/2050-7771-1-7] [Cited by in Crossref: 52] [Cited by in F6Publishing: 47] [Article Influence: 5.8] [Reference Citation Analysis]
73 Rabelo F, Oliveira CPMS, Faintuch J, Mazo DFC, Lima VMR, Stefano JT, Barbeiro HV, Soriano FG, Alves VAF, Carrilho FJ. Pro- and Anti-inflammatory Cytokines in Steatosis and Steatohepatitis. OBES SURG 2010;20:906-12. [DOI: 10.1007/s11695-010-0181-4] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.8] [Reference Citation Analysis]
74 Lee S, Lee H, Kim S, Lee J, Ha J, Choi Y, Oh H, Kim Y, Lee Y, Choi KH, Yoon Y. Intestinal Clostridioides difficile Can Cause Liver Injury through the Occurrence of Inflammation and Damage to Hepatocytes. Biomed Res Int 2020;2020:7929610. [PMID: 33005688 DOI: 10.1155/2020/7929610] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
75 Lambrecht J, Tacke F. Controversies and Opportunities in the Use of Inflammatory Markers for Diagnosis or Risk Prediction in Fatty Liver Disease. Front Immunol 2020;11:634409. [PMID: 33633748 DOI: 10.3389/fimmu.2020.634409] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
76 Gisondi P, Del Giglio M, Cozzi A, Girolomoni G. Psoriasis, the liver, and the gastrointestinal tract. Dermatol Ther. 2010;23:155-159. [PMID: 20415823 DOI: 10.1111/j.1529-8019.2010.01310.x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
77 Ono M, Saibara T. Clinical features of nonalcoholic steatohepatitis in Japan: Evidence from the literature. J Gastroenterol 2006;41:725-32. [PMID: 16988759 DOI: 10.1007/s00535-006-1876-0] [Cited by in Crossref: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.4] [Reference Citation Analysis]
78 Wang H, Lafdil F, Kong X, Gao B. Signal transducer and activator of transcription 3 in liver diseases: a novel therapeutic target. Int J Biol Sci. 2011;7:536-550. [PMID: 21552420 DOI: 10.7150/ijbs.7.536] [Cited by in Crossref: 164] [Cited by in F6Publishing: 169] [Article Influence: 14.9] [Reference Citation Analysis]
79 Baumgardner JN, Shankar K, Hennings L, Albano E, Badger TM, Ronis MJ. N-acetylcysteine attenuates progression of liver pathology in a rat model of nonalcoholic steatohepatitis. J Nutr. 2008;138:1872-1879. [PMID: 18806095 DOI: 10.1093/jn/138.10.1872] [Cited by in Crossref: 64] [Cited by in F6Publishing: 63] [Article Influence: 4.6] [Reference Citation Analysis]
80 Alter R, Antonio de Luis D, Izaola O, González Sagrado M, Conde R, Alvarez Gago T, Pacheco D, Manuel González J, Concepcion Velasco M. G308A polymorphism of TNF-alpha gene is associated with insulin resistance and histological changes in non alcoholic fatty liver disease patients. Annals of Hepatology 2010;9:439-44. [DOI: 10.1016/s1665-2681(19)31620-5] [Cited by in Crossref: 14] [Article Influence: 1.2] [Reference Citation Analysis]
81 Newell P, Villanueva A, Friedman SL, Koike K, Llovet JM. Experimental models of hepatocellular carcinoma. J Hepatol. 2008;48:858-879. [PMID: 18314222 DOI: 10.1016/j.jhep.2008.01.008] [Cited by in Crossref: 150] [Cited by in F6Publishing: 142] [Article Influence: 10.7] [Reference Citation Analysis]
82 Sangouni AA, Ghavamzadeh S. A review of synbiotic efficacy in non-alcoholic fatty liver disease as a therapeutic approach. Diabetes Metab Syndr 2019;13:2917-22. [PMID: 31425956 DOI: 10.1016/j.dsx.2019.07.063] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
83 Aliasghari F, Izadi A, Jabbari M, Imani B, Gargari BP, Asjodi F, Ebrahimi S. Are Vaspin and Omentin-1 Related to Insulin Resistance, Blood Pressure and Inflammation in NAFLD Patients? J Med Biochem 2018;37:470-5. [PMID: 30584407 DOI: 10.2478/jomb-2018-0006] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
84 Shin SK, Cho HW, Song SE, Song DK. Catalase and nonalcoholic fatty liver disease. Pflugers Arch 2018;470:1721-37. [PMID: 30120555 DOI: 10.1007/s00424-018-2195-z] [Cited by in Crossref: 19] [Cited by in F6Publishing: 15] [Article Influence: 4.8] [Reference Citation Analysis]
85 Kim HM, Kim YM, Huh JH, Lee ES, Kwon MH, Lee BR, Ko HJ, Chung CH. α-Mangostin ameliorates hepatic steatosis and insulin resistance by inhibition C-C chemokine receptor 2. PLoS One 2017;12:e0179204. [PMID: 28598982 DOI: 10.1371/journal.pone.0179204] [Cited by in Crossref: 11] [Cited by in F6Publishing: 8] [Article Influence: 2.2] [Reference Citation Analysis]
86 Gisondi P, Targher G, Zoppini G, Girolomoni G. Non-alcoholic fatty liver disease in patients with chronic plaque psoriasis. J Hepatol. 2009;51:758-764. [PMID: 19560226 DOI: 10.1016/j.jhep.2009.04.020] [Cited by in Crossref: 157] [Cited by in F6Publishing: 141] [Article Influence: 12.1] [Reference Citation Analysis]
87 Roh YS, Seki E. Chemokines and Chemokine Receptors in the Development of NAFLD. Adv Exp Med Biol 2018;1061:45-53. [PMID: 29956205 DOI: 10.1007/978-981-10-8684-7_4] [Cited by in Crossref: 18] [Cited by in F6Publishing: 27] [Article Influence: 4.5] [Reference Citation Analysis]
88 Tanaka N, Sano K, Horiuchi A, Tanaka E, Kiyosawa K, Aoyama T. Highly purified eicosapentaenoic acid treatment improves nonalcoholic steatohepatitis. J Clin Gastroenterol. 2008;42:413-418. [PMID: 18277895 DOI: 10.1097/mcg.0b013e31815591aa] [Cited by in Crossref: 165] [Cited by in F6Publishing: 78] [Article Influence: 11.8] [Reference Citation Analysis]
89 Baršić N, Lerotić I, Smirčić-Duvnjak L, Tomašić V, Duvnjak M. Overview and developments in noninvasive diagnosis of nonalcoholic fatty liver disease. World J Gastroenterol 2012; 18(30): 3945-3954 [PMID: 22912545 DOI: 10.3748/wjg.v18.i30.3945] [Cited by in CrossRef: 45] [Cited by in F6Publishing: 46] [Article Influence: 4.5] [Reference Citation Analysis]
90 Hahn J, Cheng P, Moya C, Jayaraman A, Huang Z. Investigation of IL-6 and IL-10 signalling via mathematical modelling. IET Systems Biology 2011;5:15-26. [DOI: 10.1049/iet-syb.2009.0060] [Cited by in Crossref: 23] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
91 Tanaka N, Tanaka E, Sheena Y, Komatsu M, Okiyama W, Misawa N, Muto H, Umemura T, Ichijo T, Matsumoto A, Yoshizawa K, Horiuchi A, Kiyosawa K. Useful parameters for distinguishing nonalcoholic steatohepatitis with mild steatosis from cryptogenic chronic hepatitis in the Japanese population. Liver Int. 2006;26:956-963. [PMID: 16953836 DOI: 10.1111/j.1478-3231.2006.01338.x] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
92 Wandrer F, Liebig S, Marhenke S, Vogel A, John K, Manns MP, Teufel A, Itzel T, Longerich T, Maier O, Fischer R, Kontermann RE, Pfizenmaier K, Schulze-Osthoff K, Bantel H. TNF-Receptor-1 inhibition reduces liver steatosis, hepatocellular injury and fibrosis in NAFLD mice. Cell Death Dis. 2020;11:212. [PMID: 32235829 DOI: 10.1038/s41419-020-2411-6] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 9.0] [Reference Citation Analysis]
93 Rachakonda VP, Reeves VL, Aljammal J, Wills RC, Trybula JS, DeLany JP, Kienesberger PC, Kershaw EE. Serum autotaxin is independently associated with hepatic steatosis in women with severe obesity. Obesity (Silver Spring). 2015;23:965-972. [PMID: 25865747 DOI: 10.1002/oby.20960] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 3.6] [Reference Citation Analysis]
94 Dallak MA, Bin-jaliah I, Albawardi A, Haidara MA, Sakr HF, Eid RA, Hassan WN, Al-ani B. Swim exercise training ameliorates hepatocyte ultrastructural alterations in rats fed on a high fat and sugar diet. Ultrastructural Pathology 2018;42:155-61. [DOI: 10.1080/01913123.2017.1422581] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
95 Jarrar MH, Baranova A, Collantes R, Ranard B, Stepanova M, Bennett C, Fang Y, Elariny H, Goodman Z, Chandhoke V, Younossi ZM. Adipokines and cytokines in non-alcoholic fatty liver disease: ADIPOKINES AND CYTOKINES IN NAFLD. Alimentary Pharmacology & Therapeutics 2008;27:412-21. [DOI: 10.1111/j.1365-2036.2007.03586.x] [Cited by in Crossref: 284] [Cited by in F6Publishing: 276] [Article Influence: 18.9] [Reference Citation Analysis]
96 Ajmera V, Perito ER, Bass NM, Terrault NA, Yates KP, Gill R, Loomba R, Diehl AM, Aouizerat BE; NASH Clinical Research Network. Novel plasma biomarkers associated with liver disease severity in adults with nonalcoholic fatty liver disease. Hepatology 2017;65:65-77. [PMID: 27532276 DOI: 10.1002/hep.28776] [Cited by in Crossref: 77] [Cited by in F6Publishing: 74] [Article Influence: 12.8] [Reference Citation Analysis]
97 Hassan K, Bhalla V, Regal MEE, A-Kader HH. Nonalcoholic fatty liver disease: A comprehensive review of a growing epidemic. World J Gastroenterol 2014; 20(34): 12082-12101 [PMID: 25232245 DOI: 10.3748/wjg.v20.i34.12082] [Cited by in CrossRef: 110] [Cited by in F6Publishing: 95] [Article Influence: 13.8] [Reference Citation Analysis]
98 Tosello-Trampont AC, Landes SG, Nguyen V, Novobrantseva TI, Hahn YS. Kuppfer cells trigger nonalcoholic steatohepatitis development in diet-induced mouse model through tumor necrosis factor-α production. J Biol Chem. 2012;287:40161-40172. [PMID: 23066023 DOI: 10.1074/jbc.m112.417014] [Cited by in Crossref: 253] [Cited by in F6Publishing: 153] [Article Influence: 25.3] [Reference Citation Analysis]
99 Liu YZ, Chen JK, Zhang Y, Wang X, Qu S, Jiang CL. Chronic stress induces steatohepatitis while decreases visceral fat mass in mice. BMC Gastroenterol 2014;14:106. [PMID: 24916323 DOI: 10.1186/1471-230X-14-106] [Cited by in Crossref: 14] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
100 Lee JY, Moon JH, Park JS, Lee BW, Kang ES, Ahn CW, Lee HC, Cha BS. Dietary oleate has beneficial effects on every step of non-alcoholic Fatty liver disease progression in a methionine- and choline-deficient diet-fed animal model. Diabetes Metab J 2011;35:489-96. [PMID: 22111040 DOI: 10.4093/dmj.2011.35.5.489] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.2] [Reference Citation Analysis]
101 Fu L, Bruckbauer A, Li F, Cao Q, Cui X, Wu R, Shi H, Zemel MB, Xue B. Interaction between metformin and leucine in reducing hyperlipidemia and hepatic lipid accumulation in diet-induced obese mice. Metabolism 2015;64:1426-34. [PMID: 26303871 DOI: 10.1016/j.metabol.2015.07.006] [Cited by in Crossref: 36] [Cited by in F6Publishing: 33] [Article Influence: 5.1] [Reference Citation Analysis]
102 Kim CW, Lee CD. Apoptosis and diagnosis of nonalcoholic steatohepatitis. Korean J Hepatol 2011;17:247-9. [PMID: 22102395 DOI: 10.3350/kjhep.2011.17.3.247] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
103 Song HM, Li X, Liu YY, Lu WP, Cui ZH, Zhou L, Yao D, Zhang HM. Carnosic acid protects mice from high-fat diet-induced NAFLD by regulating MARCKS. Int J Mol Med 2018;42:193-207. [PMID: 29620148 DOI: 10.3892/ijmm.2018.3593] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
104 Luyendyk JP, Sullivan BP, Guo GL, Wang R. Tissue factor-deficiency and protease activated receptor-1-deficiency reduce inflammation elicited by diet-induced steatohepatitis in mice. Am J Pathol 2010;176:177-86. [PMID: 20008134 DOI: 10.2353/ajpath.2010.090672] [Cited by in Crossref: 37] [Cited by in F6Publishing: 38] [Article Influence: 2.8] [Reference Citation Analysis]
105 Miller MH, Ferguson MAJ, Dillon JF. Systematic review of performance of non-invasive biomarkers in the evaluation of non-alcoholic fatty liver disease: Performance of non-invasive biomarkers in non-alcoholic fatty liver disease. Liver International 2011;31:461-73. [DOI: 10.1111/j.1478-3231.2011.02451.x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 31] [Article Influence: 3.1] [Reference Citation Analysis]
106 Gentile CL, Frye MA, Pagliassotti MJ. Fatty acids and the endoplasmic reticulum in nonalcoholic fatty liver disease. Biofactors 2011;37:8-16. [PMID: 21328622 DOI: 10.1002/biof.135] [Cited by in Crossref: 97] [Cited by in F6Publishing: 64] [Article Influence: 8.1] [Reference Citation Analysis]
107 Targher G, Bosworth C, Kendrick J, Smits G, Lippi G, Chonchol M. Relationship of serum bilirubin concentrations to kidney function and albuminuria in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Clin Chem Lab Med. 2009;47:1055-1062. [PMID: 19634983 DOI: 10.1515/cclm.2009.244] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 2.1] [Reference Citation Analysis]
108 Lin L, Lu J, Huang X, Ding L, Huang Y, Wang P, Peng K, Zhang D, Xu Y, Xu M, Chen Y, Bi Y, Wang W, Xu Y. Nonalcoholic fatty liver disease is associated with low-grade albuminuria in Chinese adults (change not displayed). QJM 2016;109:737-43. [DOI: 10.1093/qjmed/hcw070] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
109 Tsai E, Lee TP. Diagnosis and Evaluation of Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis, Including Noninvasive Biomarkers and Transient Elastography. Clin Liver Dis. 2018;22:73-92. [PMID: 29128062 DOI: 10.1016/j.cld.2017.08.004] [Cited by in Crossref: 34] [Cited by in F6Publishing: 28] [Article Influence: 8.5] [Reference Citation Analysis]
110 Dyson JK, Mcpherson S, Anstee QM. Non-alcoholic fatty liver disease: non-invasive investigation and risk stratification. J Clin Pathol 2013;66:1033-45. [DOI: 10.1136/jclinpath-2013-201620] [Cited by in Crossref: 50] [Cited by in F6Publishing: 44] [Article Influence: 5.6] [Reference Citation Analysis]
111 Shen B, Yu J, Wang S, Chu ES, Wong VW, Zhou X, Lin G, Sung JJ, Chan HL. Phyllanthus urinaria ameliorates the severity of nutritional steatohepatitis both in vitro and in vivo. Hepatology 2008;47:473-83. [PMID: 18157836 DOI: 10.1002/hep.22039] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.2] [Reference Citation Analysis]
112 Mollica MP, Trinchese G, Cavaliere G, De Filippo C, Cocca E, Gaita M, Della-Gatta A, Marano A, Mazzarella G, Bergamo P. c9,t11-Conjugated linoleic acid ameliorates steatosis by modulating mitochondrial uncoupling and Nrf2 pathway. J Lipid Res 2014;55:837-49. [PMID: 24634500 DOI: 10.1194/jlr.M044032] [Cited by in Crossref: 35] [Cited by in F6Publishing: 13] [Article Influence: 4.4] [Reference Citation Analysis]
113 Kim MY. [The Progression of Liver Fibrosis in Non-alcoholic Fatty Liver Disease]. Korean J Gastroenterol 2017;69:341-7. [PMID: 28637102 DOI: 10.4166/kjg.2017.69.6.341] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
114 Kwok R, Tse YK, Wong GL, Ha Y, Lee AU, Ngu MC, Chan HL, Wong VW. Systematic review with meta-analysis: non-invasive assessment of non-alcoholic fatty liver disease--the role of transient elastography and plasma cytokeratin-18 fragments. Aliment Pharmacol Ther. 2014;39:254-269. [PMID: 24308774 DOI: 10.1111/apt.12569] [Cited by in Crossref: 228] [Cited by in F6Publishing: 197] [Article Influence: 25.3] [Reference Citation Analysis]
115 Targher G, Kendrick J, Smits G, Chonchol M. Relationship between serum gamma-glutamyltransferase and chronic kidney disease in the United States adult population. Findings from the National Health and Nutrition Examination Survey 2001-2006. Nutr Metab Cardiovasc Dis. 2010;20:583-590. [PMID: 19699624 DOI: 10.1016/j.numecd.2009.05.012] [Cited by in Crossref: 40] [Cited by in F6Publishing: 41] [Article Influence: 3.1] [Reference Citation Analysis]
116 Oh MK, Winn J, Poordad F. Review article: diagnosis and treatment of non-alcoholic fatty liver disease. Alimentary Pharmacology & Therapeutics 2008;28:503-22. [DOI: 10.1111/j.1365-2036.2008.03752.x] [Cited by in Crossref: 68] [Cited by in F6Publishing: 70] [Article Influence: 4.9] [Reference Citation Analysis]
117 Fitzpatrick E, Dhawan A. Noninvasive biomarkers in non-alcoholic fatty liver disease: Current status and a glimpse of the future. World J Gastroenterol 2014; 20(31): 10851-10863 [PMID: 25152587 DOI: 10.3748/wjg.v20.i31.10851] [Cited by in CrossRef: 68] [Cited by in F6Publishing: 59] [Article Influence: 8.5] [Reference Citation Analysis]
118 Tilg H, Moschen AR. Insulin resistance, inflammation, and non-alcoholic fatty liver disease. Trends Endocrinol Metab. 2008;19:371-379. [PMID: 18929493 DOI: 10.1016/j.tem.2008.08.005] [Cited by in Crossref: 288] [Cited by in F6Publishing: 280] [Article Influence: 20.6] [Reference Citation Analysis]
119 Cimini FA, Barchetta I, Carotti S, Bertoccini L, Baroni MG, Vespasiani-Gentilucci U, Cavallo MG, Morini S. Relationship between adipose tissue dysfunction, vitamin D deficiency and the pathogenesis of non-alcoholic fatty liver disease. World J Gastroenterol 2017; 23(19): 3407-3417 [PMID: 28596677 DOI: 10.3748/wjg.v23.i19.3407] [Cited by in CrossRef: 42] [Cited by in F6Publishing: 36] [Article Influence: 8.4] [Reference Citation Analysis]
120 Seo YY, Cho YK, Bae JC, Seo MH, Park SE, Rhee EJ, Park CY, Oh KW, Park SW, Lee WY. Tumor Necrosis Factor-α as a Predictor for the Development of Nonalcoholic Fatty Liver Disease: A 4-Year Follow-Up Study. Endocrinol Metab (Seoul). 2013;28:41-45. [PMID: 24396649 DOI: 10.3803/enm.2013.28.1.41] [Cited by in Crossref: 35] [Cited by in F6Publishing: 20] [Article Influence: 3.9] [Reference Citation Analysis]
121 Meli R, Mattace Raso G, Calignano A. Role of innate immune response in non-alcoholic Fatty liver disease: metabolic complications and therapeutic tools. Front Immunol. 2014;5:177. [PMID: 24795720 DOI: 10.3389/fimmu.2014. 00177] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
122 Liu Q, Bengmark S, Qu S. The role of hepatic fat accumulation in pathogenesis of non-alcoholic fatty liver disease (NAFLD). Lipids Health Dis. 2010;9:42. [PMID: 20426802 DOI: 10.1186/1476-511x-9-42] [Cited by in Crossref: 108] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
123 Li W, Zheng L, Sheng C, Cheng X, Qing L, Qu S. Systematic review on the treatment of pentoxifylline in patients with non-alcoholic fatty liver disease. Lipids Health Dis. 2011;10:49. [PMID: 21477300 DOI: 10.1186/1476-511x-10-49] [Cited by in Crossref: 53] [Cited by in F6Publishing: 30] [Article Influence: 4.8] [Reference Citation Analysis]
124 Tilg H, Moschen AR. Relevance of TNF -α gene polymorphisms in nonalcoholic fatty liver disease. Expert Review of Gastroenterology & Hepatology 2014;5:155-8. [DOI: 10.1586/egh.11.17] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
125 Bieghs V, Rensen PC, Hofker MH, Shiri-sverdlov R. NASH and atherosclerosis are two aspects of a shared disease: Central role for macrophages. Atherosclerosis 2012;220:287-93. [DOI: 10.1016/j.atherosclerosis.2011.08.041] [Cited by in Crossref: 57] [Cited by in F6Publishing: 56] [Article Influence: 5.7] [Reference Citation Analysis]
126 Bieghs V, Van Gorp PJ, Wouters K, Hendrikx T, Gijbels MJ, van Bilsen M, Bakker J, Binder CJ, Lütjohann D, Staels B, Hofker MH, Shiri-Sverdlov R. LDL receptor knock-out mice are a physiological model particularly vulnerable to study the onset of inflammation in non-alcoholic fatty liver disease. PLoS One 2012;7:e30668. [PMID: 22295101 DOI: 10.1371/journal.pone.0030668] [Cited by in Crossref: 99] [Cited by in F6Publishing: 96] [Article Influence: 9.9] [Reference Citation Analysis]
127 Jarukamjorn K, Jearapong N, Pimson C, Chatuphonprasert W. A High-Fat, High-Fructose Diet Induces Antioxidant Imbalance and Increases the Risk and Progression of Nonalcoholic Fatty Liver Disease in Mice. Scientifica (Cairo) 2016;2016:5029414. [PMID: 27019761 DOI: 10.1155/2016/5029414] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
128 Lee SA, Lee SY, Choi YM, Kim H, Kim BJ. Sex disparity in viral load, inflammation and liver damage in transgenic mice carrying full hepatitis B virus genome with the W4P mutation in the preS1 region. World J Gastroenterol 2018; 24(10): 1084-1092 [PMID: 29563753 DOI: 10.3748/wjg.v24.i10.1084] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
129 Semba T, Nishimura M, Nishimura S, Ohara O, Ishige T, Ohno S, Nonaka K, Sogawa K, Satoh M, Sawai S, Matsushita K, Imazeki F, Yokosuka O, Nomura F. The FLS (fatty liver Shionogi) mouse reveals local expressions of lipocalin-2, CXCL1 and CXCL9 in the liver with non-alcoholic steatohepatitis. BMC Gastroenterol 2013;13:120. [PMID: 23875831 DOI: 10.1186/1471-230X-13-120] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]